The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| CRISPR THERAPEUTICS AG | NAMEN AKT | H17182108 | BBG00DBBGRX1 | 7,751,700 | 165,000 | SH | SOLE | 165,000 | 0 | 0 | ||
| ASML Holding NV | N Y REGISTRY SHS | N07059210 | BBG000C1HT47 | 92,005,659 | 110,835 | SH | SOLE | 110,835 | 0 | 0 | ||